Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy

2020 ◽  
Vol 40 (9) ◽  
pp. 5291-5294 ◽  
Author(s):  
UMAIR M. NASIR ◽  
ALEXANDER M. MOZEIKA ◽  
MUTLAY SAYAN ◽  
IMRAAN JAN ◽  
NOEL KOWAL ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy ◽  
Gastrointestinal Mucositis

scholarly journals S1951 Concurrent Palbociclib and Palliative Radiation Therapy Leading to Severe Gastrointestinal Mucositis

2020 ◽  
Vol 115 (1) ◽  
pp. S1016-S1017
Author(s):  
Umair M. Nasir ◽  
Alexander Mozeika ◽  
Imraan Jan ◽  
Catherine Choi ◽  
Shima Ghavimi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy ◽  
Gastrointestinal Mucositis

scholarly journals Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

2020 ◽  
Vol 8 (2) ◽  
pp. e001095 ◽  
Author(s):  
Lillian Siu ◽  
Joshua Brody ◽  
Shilpa Gupta ◽  
Aurélien Marabelle ◽  
Antonio Jimeno ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Solid Tumors ◽  
Phase 1 ◽  
Objective Response ◽  
Clinical Activity ◽  
Advanced Solid Tumors ◽  
Palliative Radiation ◽  
Cell Counts ◽  
Palliative Radiation Therapy ◽  
Grade 3

BackgroundMEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist. In mice, MEDI9197 modulated antitumor immune responses, inhibited tumor growth and increased survival. This first-time-in-human, phase 1 study evaluated MEDI9197 with or without the programmed cell death ligand-1 (PD-L1) inhibitor durvalumab and/or palliative radiation therapy (RT) for advanced solid tumors.Patients and methodsEligible patients had at least one cutaneous, subcutaneous, or deep-seated lesion suitable for intratumoral (IT) injection. Dose escalation used a standard 3+3 design. Patients received IT MEDI9197 0.005–0.055 mg with or without RT (part 1), or IT MEDI9197 0.005 or 0.012 mg plus durvalumab 1500 mg intravenous with or without RT (part 3), in 4-week cycles. Primary endpoints were safety and tolerability. Secondary endpoints included pharmacokinetics, pharmacodynamics, and objective response based on Response Evaluation Criteria for Solid Tumors version 1.1. Exploratory endpoints included tumor and peripheral biomarkers that correlate with biological activity or predict response.ResultsFrom November 2015 to March 2018, part 1 enrolled 35 patients and part 3 enrolled 17 patients; five in part 1 and 2 in part 3 received RT. The maximum tolerated dose of MEDI9197 monotherapy was 0.037 mg, with dose-limiting toxicity (DLT) of cytokine release syndrome in two patients (one grade 3, one grade 4) and 0.012 mg in combination with durvalumab 1500 mg with DLT of MEDI9197-related hemorrhagic shock in one patient (grade 5) following liver metastasis rupture after two cycles of MEDI9197. Across parts 1 and 3, the most frequent MEDI9197-related adverse events (AEs) of any grade were fever (56%), fatigue (31%), and nausea (21%). The most frequent MEDI9197-related grade ≥3 events were decreased lymphocytes (15%), neutrophils (10%), and white cell counts (10%). MEDI9197 increased tumoral CD8+ and PD-L1+ cells, inducing type 1 and 2 interferons and Th1 response. There were no objective clinical responses; 10 patients in part 1 and 3 patients in part 3 had stable disease ≥8 weeks.ConclusionIT MEDI9197 was feasible for subcutaneous/cutaneous lesions but AEs precluded its use in deep-seated lesions. Although no patients responded, MEDI9197 induced systemic and intratumoral immune activation, indicating potential value in combination regimens in other patient populations.Trial registration numberNCT02556463.

Survival after palliative radiation therapy for cancer: the METSSS model

2021 ◽  
Author(s):  
Nicholas G. Zaorsky ◽  
Menglu Liang ◽  
Rutu Patel ◽  
Christine Lin ◽  
Leila T. Tchelebi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy

Choosing Wisely at the End of Life: Use of Shorter Courses of Palliative Radiation Therapy for Bone Metastasis

2018 ◽  
Vol 102 (2) ◽  
pp. 320-324 ◽  
Author(s):  
Audrey S. Wallace ◽  
John B. Fiveash ◽  
Courtney P. Williams ◽  
Elizabeth Kvale ◽  
Maria Pisu ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Bone Metastasis ◽  
End Of Life ◽  
Choosing Wisely ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy

scholarly journals EP-1444: Short-course accelerated palliative radiation therapy for advanced solid cancers in elderly patients

2016 ◽  
Vol 119 ◽  
pp. S670
Author(s):  
L. Caravatta ◽  
G. Torre ◽  
F. Deodato ◽  
J. Capuccini ◽  
A. Farioli ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Elderly Patients ◽  
Palliative Radiation ◽  
Short Course ◽  
Palliative Radiation Therapy

Position of Appetite and Nausea in Symptom Clusters in Palliative Radiation Therapy

2019 ◽  
pp. 261-273
Author(s):  
Selina Chow ◽  
Vithusha Ganesh ◽  
Carlo DeAngelis ◽  
Caitlin Yee ◽  
Henry Lam ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Symptom Clusters ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy
Sign in / Sign up

Export Citation Format

Share Document